Kaleido Biosciences, Inc. (KLDO)
| Market Cap | 268.51M |
| Revenue (ttm) | 1.27M |
| Net Income (ttm) | -85.11M |
| Shares Out | 42.52M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $6.32 |
| Previous Close | $5.82 |
| Change ($) | 0.50 |
| Change (%) | 8.51% |
| Day's Open | 5.89 |
| Day's Range | 5.80 - 6.69 |
| Day's Volume | 260,140 |
| 52-Week Range | 5.04 - 20.50 |
--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...
Biotech company Kaleido develops oral therapy for COVID-19
Dan Menichella, Kaleido CEO, joins Yahoo Finance's Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability...
KB109 demonstrated favorable safety and tolerability profile
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021
LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.
LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symp...
Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities
LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan He...
Topline data for two studies of KB109 are expected in the first quarter of 2021 Topline data for two studies of KB109 are expected in the first quarter of 2021
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the vir...
- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 -
Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020
LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added t...
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat di...
Why Kaleido Stock Is Taking Off, And Why It Can Go Higher
Top-line safety, tolerability and activity results expected in mid-2021 Top-line safety, tolerability and activity results expected in mid-2021
LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferen...
LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic encephalopat...
- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 -
- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter
LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat ...
Kaleido Biosciences, Inc. (KLDO) CEO Alison Lawton on Q1 2020 Results - Earnings Call Transcript
- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -
- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -
LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Is (KLDO) Outperforming Other Medical Stocks This Year?
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ ...
About KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The ... [Read more...]
| Industry Biotechnology | IPO Date Feb 28, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol KLDO |
Analyst Forecasts
According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 16.14, which is an increase of 155.58% from the latest price.